Ovarian Suppression Formulation Change in Young Breast Cancer
Part of Cancer, Skin clinical trials.
This study tests whether switching the type of ovarian-suppressing medication helps keep hormone-sensitive breast cancer under control in younger women. You'll be screened to see if your current treatment is working, then potentially switched to a different formulation to see if it works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Female, between 18 and 45 years old
- Hormone-sensitive, HER2-negative early breast cancer (stage I–III) confirmed by biopsy
- Surgery completed; any chemotherapy or radiation therapy already finished
- Currently taking a 3-month ovarian-suppressing injection (GnRH agonist) plus a hormone-blocking pill, for at least 1 dose
- Hormone level (estradiol) measured as ≥30 pg/mL within the past 4 weeks
- Good overall health and organ function; able to attend follow-up visits
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies the safety of continuing endocrine therapy with ovarian suppression (for women) after you finish the earlier OVELIA study. It may help doctors confirm that the treatment remains safe for longer-term use.
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
This Phase 2 study tests whether using hormone (endocrine) treatment alone can control breast cancer in people age 70 and older. It targets breast cancers that are estrogen-receptor positive and HER2 negative, aiming to avoid chemotherapy-like treatments in suitable patients.
This trial tests a new oral drug (HRS-8080) against standard hormone therapy for women with intermediate- or high-risk early breast cancer who have already completed 2 to 5 years of hormone treatment. It aims to see if the new drug can reduce the risk of cancer coming back.
This trial tests whether switching to a different aromatase inhibitor or using standard treatments works better for managing side effects in breast cancer survivors. It aims to help you stay on hormone therapy longer with fewer discomforts.
This trial tests a new drug called HRS-6209 combined with other treatments for people with breast cancer that has worsened after previous therapy. It aims to find a more effective way to control the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.